Compass Pathways Eyes Rolling FDA Filing for COMP360, Preps TRD Launch Ahead of Q3 Data
Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch preparation for its investigational psilocybin therapy, COMP360, during a recent fireside chat. Chief Executive Officer Kabir Nath and Chief Commercial Officer Lori Englebert discuss...